To provide the potential for reliable growth by tracking the performance of those companies in the FTSE World Index which are engaged in Health, Pharmaceuticals and Biotechnology.
Name | % Net Assets |
---|---|
Johnson & Johnson | 8.4% |
Pfizer Inc. | 5.4% |
Roche Holding AG | 5.1% |
GlaxoSmithKline PLC | 4.9% |
Novartis | 4.9% |
Pfizer | 3.9% |
AstraZeneca PLC | 3.4% |
Wyeth | 3.3% |
Merck & Co., Inc | 3.2% |
Sanofi-Aventis | 3.1% |
Key | % Net Assets |
---|---|
Johnson & Johnson | 8.4% |
Pfizer Inc. | 5.4% |
Roche Holding AG | 5.1% |
GlaxoSmithKline PLC | 4.9% |
Other | 76.2% |
Date | 21-Nov-2024 |
---|---|
NAV | 129.40p |
Currency | GBP |
Change | 1.60p |
% | 1.25% |
YTD change | 4.00p |
YTD % | 3.19% |
Fund Inception | 01/11/2000 |
---|---|
Fund Manager | Ali Toutounchi |
TER | 0.31 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.30% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.07 |
You are here: research